Compare Novo Nordisk A/S (NVO) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Growth Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Vanguard Growth Index Fund ETF trades at $91.97 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 2.3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| NVO | VUG | |
|---|---|---|
Market Cap | $165.31B | $384.60B |
Volume | 11,432,838 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $92.64 |
52-Week Low | $35.29 | $70.00 |
Typical Hold Time | 116 Days | 47 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
VUG trades at $91.31, down 1.2% on the day, with a bullish technical signal supported by moving averages. The ETF maintains strong long-term performance with historical annual returns around 11-12% since inception. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings. The fund's low 0.03% expense ratio appeals to cost-conscious investors seeking growth exposure.
VUG offers compelling long-term growth potential for investors with multi-decade horizons, though its heavy tech concentration presents both opportunity and risk. While historical performance has outpaced the broader market, current market conditions show value funds outperforming growth strategies in 2026. The ETF remains suitable for buy-and-hold investors seeking large-cap growth exposure with minimal fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
